The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Published Date: 08 Apr 2024

In three trials, the response rate was about half the patients, and it lasted for up to 19 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Two-part prodrug system activates immune attack only in tumor's unique environment

2.

Oleanolic acid from grapes may increase chemotherapy effectiveness

3.

Obesity-related cancer rising among both younger and older adults worldwide, study finds

4.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

5.

Combination therapy improves outcomes for advanced triple-negative breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot